The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution
Duy D. NguyeniD, William F. HooperiD, Timothy R. ChuiD, Heather M. GeigeriD, Jennifer Marie SheltoniD, Minita J. Shah, Zoe R. GoldsteiniD, Lara Heermans WinterkorniD, Michael SigourosiD, Jyothi ManohariD, Jenna E. MoyeriD, David C. WilkesiD, Rahul Raman SinghiD, Weisi LiuiD, Andrea SboneriD, Scott T. TagawaiD, David M. NanusiD, Jones Trevor NauseefiD, Cora Nanette SternbergiD, Ana M. MolinaiD, Douglas S. ScherriD, Giorgio InghiramiiD, Juan Miguel MosqueraiD, Olivier ElementoiD, Nicolas RobineiD, Bishoy M. FaltasiD
Abstract
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity. In this study, we investigate the evolution of the genomic signatures caused by endogenous and external mutagenic stimuli and their interplay with complex structural variants. We superimposed mutational signatures and phylogenetic analyses of matched serial tumors from patients with urothelial cancer to define the evolutionary patterns of these processes. We show that APOBEC3-induced mutations are clonal and early, whereas mutational bursts comprising hundreds of late subclonal mutations are induced by chemotherapy. Using a novel genome graph computational paradigm, we observed frequent circular high copy-number amplicons characteristic of extrachromosomal DNA (ecDNA) involving double-minutes, breakage-fusion-bridge, and tyfonas events. We characterized the distinct temporal patterns of APOBEC3 mutations and chemotherapy-induced mutations within ecDNA, gaining new insights into the timing of these events relative to ecDNA biogenesis. Finally, we discovered that most CCND1 amplifications in urothelial cancer arise within circular ecDNA amplicons. These CCND1 ecDNA amplification events persisted and increased in complexity incorporating additional DNA segments potentially contributing selective fitness advantage to the evolution of treatment resistance. Our findings define fundamental mechanisms driving urothelial cancer evolution and have therapeutic implications for treating this disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- APOBEC-Mediated Mutagenesis In Urothelial Carcinoma Is Associated With Improved Survival, Mutations In DNA Damage Response Genes, And Immune Response
A. P. Glaser, D. Fantini, … J. J. Meeks·bioRxiv·Apr 4, 2017
- The cytidine deaminase APOBEC3G drives cancer mutagenesis and clonal evolution in bladder cancer
Weisi Liu, Kevin P. Newhall, … Bishoy M. Faltas·bioRxiv·Sep 5, 2022
- Aberrant inheritance of extrachromosomal DNA amplifications promotes cancer evolution
Shir Marom, I. DAYAN, … Ofer Shoshani·bioRxiv·Sep 19, 2025
- Comprehensive analysis of clustered mutations in cancer reveals recurrent APOBEC3 mutagenesis of ecDNA
E. N. Bergstrom, J.-C. Luebeck, … L. B. Alexandrov·bioRxiv·May 27, 2021
- Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway
Yue Wang, Oliver Cope, … Elizabeth Brunk·bioRxiv·Apr 26, 2025
- Stochastic dynamics of extra-chromosomal DNA
Y. Pichugin, W. Huang, B. Werner·bioRxiv·Dec 15, 2019